Status:

RECRUITING

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Lead Sponsor:

Almirall, S.A.

Conditions:

Plaque Psoriasis

Eligibility:

All Genders

18+ years

Brief Summary

The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior ...

Eligibility Criteria

Inclusion

  • Written informed consent.
  • \>=18 years of age.
  • Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
  • Switch to tildrakizumab due to:
  • primary or secondary treatment failure (PASI \>= 3 or ΔPASI \< 75 and/or DLQI \> 5)
  • adverse events, contraindication, intolerance
  • patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason
  • Treatment with tildrakizumab planned in the frame of clinical practice.

Exclusion

  • Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
  • \>=3 previous biologic treatments in the last 3 years.
  • Participation in a clinical trial simultaneous to participation in SW-ATCH.
  • Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.
  • Patient dependent on the Investigator.
  • Previous treatment with Tildrakizumab.

Key Trial Info

Start Date :

September 6 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 1 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06030076

Start Date

September 6 2023

End Date

October 1 2025

Last Update

January 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gesundheitszentrum Citypark Graz

Graz, Styria, Austria, 8010